Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Roger M. Lyons et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based StudyStephen J. Noga, Ralph V. Boccia, Robert M. Rifkin et al.|Blood|2019Cited by 4
PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)Robert M. Rifkin, Ralph V. Boccia, Habte Yimer et al.|HemaSphere|2019Cited by 1